Pfizer recalls HRT batches over packaging concerns
Pfizer is recalling two batches of its oestrogen replacement product Duavive due to concerns around faulty packaging, the Medicines and Healthcare products Regulatory Agency (MHRA) has said.
The recall, which was announced today as a precautionary measure, affects batches AH1573 (expiry date August 2021) and W96114 (September 2020) of 28-size packs of Duavive 0.45mg/20mg modified release tablets.
During the manufacturerâ€™s stability studies â€œan evaluation of the foil laminate pouch identified oxygen levels above the specified limits, resulting in lower dissolution results for bazedoxifene acetate,â€ explained the MHRA.
Remaining stock of these batches should be quarantined and returned to Pfizer for credit says the MHRA.
This interactive video will test and reinforce your knowledge so you can confidently advise parents on common childhood illnesses, such as teething, earache, coughs and colds.
This module will improve your hay fever knowledge, helping you to understand its impact on sufferers and recommend the right products to ease symptoms